Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2+ Metastatic Breast Cancer (MBC) 1

Interventions

pembrolizumab 37 Carboplatin 31 Cisplatin 30 Paclitaxel 23 Nivolumab 21 Pemetrexed 21 Dexamethasone 18 Gemcitabine 18 Ipilimumab 15 Docetaxel 13 Fluorouracil 13 Capecitabine 12 Rituximab 12 Cyclophosphamide 10 Cytarabine 10 Trastuzumab 9 atezolizumab 9 daratumumab 9 olaparib 9 130-nm albumin-bound paclitaxel 8 Lenalidomide 8 Prednisone 8 durvalumab 8 trastuzumab deruxtecan 8 Bevacizumab 7 Bortezomib 7 Fulvestrant 7 Oxaliplatin 7 Vinorelbine 7 cabozantinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Has announcements × Lapatinib × Clear all

NCT01808573 2021-06-11

NALA

Puma Biotechnology, Inc.

Phase 3 Completed

621 enrolled 21 charts 1 FDA

HER2+ Metastatic Breast Cancer (MBC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡